Table 3.
Association between ABCG2 haplotype and diplotype and objective response
| Haplotype or Diplotypea | Response (CR+PR/SD+PD) | P-valueb | OR (95% CI)c | P-valuec |
|---|---|---|---|---|
| Haplotype frequency | ||||
| Hap1_AC | 127/596 | 0.605 | 1.00 | |
| Hap2_AA | 130/484 | 0.019 | 1.45 (1.10-1.90) | 0.008 |
| Hap3_GC | 97/516 | 0.071 | 1.08 (0.62-1.88) | 0.781 |
| Diplotype frequency | ||||
| Non-Hap2 carriers | 104/530 | 0.005 | 1.00 | |
| Hap2-Others carriers | 44/201 | 1.10 (0.73-1.65) | 0.643 | |
| Hap2-Hap2 carriers | 29/67 | 2.13 (1.28-3.55) | 0.004 | |
a Haplotypes were predicted with PHASE basing on rs1871744(A/G) and rs2231142 (C/A) that were associated with ORR outcomes
b P-values of Pearson χ2 test for the difference in haplotype and diplotype frequencies.
c Odds ratios (OR) and their 95% confidence intervals (CIs) and P values were calculated with unconditional logistic regression analysis, with adjustment of gender, age, smoking status, ECOG performance status, TNM status, histological types, and treatment regimen.